Nov 28, 2023 7:00 am EST Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
Nov 09, 2023 7:00 am EST Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
Oct 02, 2023 4:52 pm EDT Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 26, 2023 6:00 am EDT Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Sep 25, 2023 11:01 pm EDT Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
Aug 10, 2023 7:00 am EDT Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
May 22, 2023 7:00 am EDT Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023